Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 25 for “"Factor VIII"”.
-
SUBLINGUAL IMMUNOTHERAPY INDUCES TOLERANCE TO FACTOR VIII IN HEMOPHILIA A MICE
… or decreased amount of functional coagulation Factor VIII (FVIII) in the blood. The clinical manifestations of HA include uncontrolled bleeding events, spontaneous muscle bleeding, and joint bleeding leading to the painful swelling of joints. There is currently no cure for HA, the treatment for …
-
Characterization of the Recombinant Human Factor VIII Expressed in the Milk of Transgenic Swine
Factor VIII is a protein which has therapeutic applications for the treatment of Hemophilia A. Its deficiency, either qualitative or quantitative, results in Hemophilia A, a disorder affecting approximately 1 in 10,000 males. Currently, FVIII replacement therapy uses FVIII derived from plasma or …
-
Infusing Factor Viii-Expressing Platelets Or Megakaryocytes As A Novel Therapeutic Strategy For Hemophilia A
… A, a deficiency of functional coagulation factor VIII. Patients with severe hemophilia A suffer from recurrent bleeding with significant morbidity and mortality with 20-30% of these patients developing antibodies to infused Factor (F) VIII therapy. One area of on-going research for …
-
INFLUENCE OF LIPOPROTEIN LIPIDS AND APOLIPOPROTEIN E GENE POLYMORPHISMS ON COAGULATION FACTOR VIII CHANGES WITH SIX MONTHS OF AEROBIC EXERCISE TRAINING
… E GENE POLYMORPHISMS ON COAGULATION FACTOR VIII CHANGES WITH SIX MONTHS OF AEROBIC EXERCISE TRAINING. Rakesh Gopinathannair, Master of Arts, 2004. Thesis directed by: Professor James M. Hagberg, Ph.D., Dept. of Kinesiology Elevated plasma factor VIII antigen (FVIII:Ag) level is an …
-
An integrated process for the recovery of clinically significant trace proteins from human plasma
Methods for the preparation of concentrates of factor VIII, factor IX, high purity factor IX, Cl esterase inhibitor, specific immunoglobulin and platelet factor XIII are described. These procedures were developed or modified with the aim of integration into an automated process that would allow …
-
Effects of light-emitting diode photostimulation on burn wound healing
… proliferation and secretion of pro-angiogenic factors, will restore perfusion by increasing angiogenesis. \r\nAn in vitro inflammatory model and in vivo rodent thermal injury model were treated with LED at 670nm, 730nm, 880nm, or combination-670nm/730nm/880nm. Conditioned media were analyzed …
-
Effect of Levothyroxine Administration on Hemostatic Analytes in Doberman Pinschers with von Willebrand's Disease
… supplementation increases plasma von Willebrand factor (vWf) concentration and enhances vWf function. The effects of levothyroxine administration were evaluated in 8 euthyroid Doberman Pinschers with plasma vWf concentration <30%. Levothyroxine (0.04mg/kg PO q12hours) and placebo were …
-
The Role of YAP/TAZ in von Willebrand Factor Gene Expression
von Willebrand Factor (VWF) is a large multimeric glycoprotein with important procoagulant roles in the circulation, including mediating platelet adhesion at sites of vascular injury and stabilizing Factor VIII in the plasma. VWF expression and activity is critically regulated to protect against …
-
A platelet-mediated paradigm for the targeted delivery of microencapsulated, clot-augmenting biotherapeutics
… to deliver the pro-clotting biotherapeutic, factor VIII (fVIII) for hemophilia A patients who have developed inhibitory anti-fVIII antibodies. The polyelectrolyte multilayer capsules physically shield the encapsulated fVIII from the patient’s inhibitors during circulation, preserving its …
-
Improving the Safety and Efficacy of AAV Gene Therapy for Hemophilia A
… We hypothesized that selective pressures keep factor VIII (FVIII) activity low. Using criteria established from studies of factor IX-Padua, a factor IX transgene with increased specific activity, we identified 52 amino acids we hypothesized would lead to increased FVIII activity when …
-
Thrombophilie als mögliche Ursache für vorzeitige Plazentalösung
… or who were pregnant. Under consideration of all factors for thrombophilia 45 women (80.36%) showed abnormalities in screening, 20 women (35.71%) had combined defects. Overall 26 women (46.43%) had either a factor V suffering, a prothrombin or MTHFR mutation or were carrier of the PAI 4G/4G …
-
Phosphatidylserine-Based Nanoparticles For Tolerance Induction Towards Therapeutic Proteins
… towards therapeutic proteins. Factor VIII (FVIII) served as the model protein, as the dysfunction or deficiency of FVIII manifests in Hemophilia A (HA). Despite enzyme replacement therapy as the first line of therapy, about 30% of severe HA patients develop neutralizing (NAbs) …
-
Evaluation of the determinants and characterization of bleeding in hemophilia A and B carriers
… disorders caused by a deficiency in coagulation factor VIII (FVIII) or coagulation factor IX (FIX), respectively. Due to the X-linked inheritance pattern, males are affected with the disease, while females are almost exclusively carriers of hemophilia. Although carriers were historically assumed …
-
Understanding the Role of von Willebrand Factor (VWF) in Angiogenesis and Angiodysplasia
von Willebrand factor (VWF) is a large multimeric glycoprotein essential for hemostasis, mediating platelet adhesion to sites of vascular injury and stabilizing coagulation factor VIII (FVIII) in circulation. Deficiency or dysfunction of VWF results in von Willebrand disease (VWD), the most common …
-
Stimulation Through Tlr4 Increases Fviii Inhibitor Formation In A Mouse Model of Hemophilia A
… A is a clotting disorder caused by functional factor VIII (FVIII) deficiency. About 25% of patients treated with therapeutic recombinant FVIII develop antibodies (inhibitors) that render subsequent FVIII treatments ineffective. The immune mechanisms of inhibitor formation are not entirely …
-
Inflammatory processes and risk of cancer: epidemiological research.
… such as white blood cells, fibrinogen, factor VIII, von Willebrand factor, and C-reactive protein (CRP) (positive reactants) and decreased levels of albumin (a negative reactant) are associated with increased risk of subsequent colorectal cancer (CRC) in a prospective cohort - ARIC. …
-
Molecular Characterization and Inhibition of Antibodies Elicited Against Galactosyltransferase Knockout Pig Xenografts
… human antibodies capable of inhibiting clotting factor VIII (FVIII). Therefore, we subsequently identified FVIII as a novel xenoantigen, and provided a preliminary molecular analysis of the interaction between FVIII and the antibodies elicited after xenotransplantation. Additionally, our analyses …
-
FVIII Immunity : early events and tolerance mechanisms to FVIII
… for hemophilia A, the development of anti-FVIII antibodies including “FVIII inhibitors” remains the major clinical problem in treating hemophiliacs. Factor VIII inhibitors work through neutralizing the coagulation cofactor activity of the infused FVIII and preventing the restoration of …
-
FUNCTIONAL STUDIES WITH DIRECT ORAL ANTICOAGULANTS: INVESTIGATION OF THE REGULATION OF KEY BLOOD COAGULATION PROTEASES
… The binding of rivaroxaban and apixaban to factor Xa is nearly identical; both interact with the active site with comparable affinity. Despite this, a 3-fold faster rate of the rivaroxaban on-rate yields significantly greater prolongation of the prothrombin time (PT) and activated partial …
-
Exploring Anti-FVIII Antibodies in Haemophilia A - Role in In Vitro Haemostasis and Clinical Disease
… is caused by defective synthesis of coagulation factor VIII(FVIII), which has serious effects on haemostasis; joints being the most common site of bleeding. The development of FVIII replacements has improved the situation for patients with haemophilia such that chronic arthropathy can be …
Page 1 of 2